2,851
edits
Nicotinamide Mononucleotide (NMN): Difference between revisions
Nicotinamide Mononucleotide (NMN) (view source)
Revision as of 21:28, 15 November 2023
, 15 November 2023→Clinical Trials
| Line 242: | Line 242: | ||
|{{pmid_text|35182418}} | |{{pmid_text|35182418}} | ||
|[[RCT]], 14 days | |[[RCT]], 14 days | ||
* | *1g MIB-626 once daily | ||
* | *1g MIB-626 twice daily | ||
*placebo | *placebo | ||
| | | | ||
| Line 255: | Line 255: | ||
*Very little unmodified NMN excreted in urine | *Very little unmodified NMN excreted in urine | ||
*Facilitates design of efficacy trials in disease conditions | *Facilitates design of efficacy trials in disease conditions | ||
|- | |||
|{{pmid_text|36740954}} | |||
|[[RCT]], 28 days | |||
*500mg MIB-626 twice daily | |||
*placebo | |||
| | |||
*30 overweight or obese adults | |||
*≥45 years | |||
| | |||
*MIB-626 treatment increased circulating NAD and metabolites | |||
*No significant change in muscle strength, muscle fatigability, aerobic capacity, and stair-climbing power | |||
*Significant reduction in body weight, diastolic blood pressure, total LDL, and non-HDL cholesterol | |||
*Insulin sensitivity and hepatic and intra-abdominal fat unchanged | |||
*Adverse events similar between groups | |||
*Provides rationale for larger trials on NAD augmentation for cardiometabolic outcomes in older adults | |||
|} | |} | ||